For personal use only

Enrollment Initiated in Expanded FANTOM II Trial

Multiple Fantom scaffolds implanted in patient

Sydney, Australia and San Diego, California (Wednesday, 26 April 2017 AEST) – REVA Medical, Inc. (ASX: RVA) ("REVA" or the "Company") is pleased to announce the first patient enrollment in the expanded FANTOM II clinical trial. This arm of the trial is evaluating the safety and effectiveness of the Company's *Fantom* bioresorbable scaffold in complex cases that include multiple vessels and long lesions; up to 50 patients will be enrolled in Germany. The primary endpoint for these patients is the rate of Major Adverse Cardiac Events ("MACE") at a six-month time point.

Dr. Matthias Lutz, a trial investigator from the Universitätsklinikum Schleswig-Holstein in Kiel Germany, performed the first implant. The patient presented with diffuse disease in the right coronary artery, with a total lesion length in excess of 50 millimeters, and was successfully treated with three 24mm *Fantom* scaffolds.

Commenting on the procedure, Dr. Lutz stated, "The scaffolds were clearly visible during the procedure, allowing for accurate placement of multiple scaffolds without relying on marker band alignment, the method we use when implanting other scaffolds that are not visible. *Fantom's* thin struts aided in the delivery of the device through the diseased vessel, and absolutely no resistance was encountered when overlapping scaffolds, which helped ensure the success of the procedure."

This first case will be highlighted by Dr. Lutz during REVA's sponsored symposium at the upcoming EuroPCR conference, which will be held in May in Paris, France.

About REVA

REVA is a medical device company located in San Diego, California, USA, that has developed a proprietary bioresorbable scaffold, as an alternative to metal stents, to treat coronary artery disease. Scaffolds provide restoration of blood flow, support the artery through the healing process, then disappear (or "resorb") from the body over a period of time. This resorption allows the return of natural movement and function of the artery, a result not attainable with permanent metal stents. The Company's *Fantom*® scaffold has been designed to offer an ideal balance of thinness and strength, with distinct ease-of-use features including complete scaffold visibility under x-ray, expansion with one continuous inflation, and no procedural time limitations.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management. All statements that are not statements of historical fact, including those statements that address future operating performance and events or developments that we expect or anticipate will occur in the future, are forward-looking statements, such as those statements regarding our ability to commercialize current products, develop and commercialize new products, timely and successfully complete clinical trials, obtain additional regulatory

approvals, protect our intellectual property position, recruit and retain key personnel, and estimates regarding our capital requirements and financial performance. Readers should not place undue reliance on forward-looking statements. Although management believes forward-looking statements are reasonable as and when made, forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to vary materially from those expressed in forward-looking statements, including the risks and uncertainties that are described in the "Risk Factors" section of our Annual Report on Form 10-K filed with the US Securities and Exchange Commission (the "SEC") on February 27, 2017. Any forward-looking statements in this announcement speak only as of the date when made. REVA does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

United States
Investor & Media Enquiries:
REVA Medical, Inc.
Cheryl Liberatore
Director, Communications
+1 858-966-3045

Australia
Investor Enquiries:
Inteq Limited
Kim Jacobs
+61 438 217 279
Andrew Cohen
+61 408 333 452

Australia
Media Enquiries:
Buchan Consulting
Rebecca Wilson
+61 3 9866 4722

For personal use only